Chairman , HKEX

Laura M Cha is Chairman of Hong Kong Exchanges and Clearing Ltd and a member of the Financial Leaders Forum in Hong Kong.

Mrs Cha is also an Independent Non-Executive Director of Ant Group Co Ltd, a Senior International Advisor of Foundation Assets Management Sweden AB and a member of Sotheby’s International Advisory Board. In addition, she is also Vice Chairman of the International Advisory Council of the China Securities Regulatory Commission, and a Director of the World Federation of Exchanges.

Mrs Cha became the first, and to-date, the only person outside Mainland China to join the Central Government of the People’s Republic of China at the vice ministerial rank when she was appointed as Vice Chairman of the China Securities Regulatory Commission in January 2001. She served in that position until 2004. Mrs Cha worked for the Securities and Futures Commission in Hong Kong from 1991 to 2000, becoming its Deputy Chairman in 1998.

Mrs Cha was a member of Executive Council of the Government of Hong Kong from 2004 to 2022. She was also Chairman of The Financial Services Development Council of Hong Kong from January 2013 to July 2018, and Chairman of the University Grants Committee from 2007 to 2011.

Mrs Cha was awarded a Silver Bauhinia Star in 2001, a Gold Bauhinia Star in 2009 and the Grand Bauhinia Medal in 2017 by the Hong Kong Government for her public service.

Laura M Cha is Chairman of Hong Kong Exchanges and Clearing Ltd and a member of the Financial Leaders Forum in Hong Kong.

Mrs Cha is also an Independent Non-Executive Director of Ant Group Co Ltd, a Senior International Advisor of Foundation Assets Management Sweden AB and a member of Sotheby’s International Advisory Board. In addition, she is also Vice Chairman of the International Advisory Council of the China Securities Regulatory Commission, and a Director of the World Federation of Exchanges.

Mrs Cha became the first, and to-date, the only person outside Mainland China to join the Central Government of the People’s Republic of China at the vice ministerial rank when she was appointed as Vice Chairman of the China Securities Regulatory Commission in January 2001. She served in that position until 2004. Mrs Cha worked for the Securities and Futures Commission in Hong Kong from 1991 to 2000, becoming its Deputy Chairman in 1998.

Mrs Cha was a member of Executive Council of the Government of Hong Kong from 2004 to 2022. She was also Chairman of The Financial Services Development Council of Hong Kong from January 2013 to July 2018, and Chairman of the University Grants Committee from 2007 to 2011.

Mrs Cha was awarded a Silver Bauhinia Star in 2001, a Gold Bauhinia Star in 2009 and the Grand Bauhinia Medal in 2017 by the Hong Kong Government for her public service.

Under Secretary for Innovation, Technology and Industry, HKSAR Government

Ms. Lillian Cheong joined the Government in 2017 as Political Assistant to the Secretary for Innovation and Technology and was appointed as Under Secretary for Innovation, Technology and Industry in July, 2022. 

Before joining the Government, Ms. Cheong served as Assistant to Executive Director and Joint General Manager at a listed company, and had experience in operation and management of real estate development, cross-boundary retail, technology investment, business development and restructuring, digital transformation, investor relations, etc. In addition to profound knowledge in the business sector, Ms. Cheong has extensive public service experience including serving as a co-opted member of the Community Building Committee of the Wan Chai District Council, adviser to a think tank, etc.

Ms. Lillian Cheong joined the Government in 2017 as Political Assistant to the Secretary for Innovation and Technology and was appointed as Under Secretary for Innovation, Technology and Industry in July, 2022. 

Before joining the Government, Ms. Cheong served as Assistant to Executive Director and Joint General Manager at a listed company, and had experience in operation and management of real estate development, cross-boundary retail, technology investment, business development and restructuring, digital transformation, investor relations, etc. In addition to profound knowledge in the business sector, Ms. Cheong has extensive public service experience including serving as a co-opted member of the Community Building Committee of the Wan Chai District Council, adviser to a think tank, etc.

Chief Executive Officer , HKEX

Nicolas Aguzin joined HKEX as Chief Executive Officer on 24 May 2021 from J.P. Morgan, where he was most recently Chief Executive Officer of J.P. Morgan’s International Private Bank. Mr Aguzin has been based in Hong Kong since 2012.

From 2013 to 2020, Mr Aguzin was CEO, J.P. Morgan, Asia Pacific where he was responsible for all the firm’s business across 17 markets. Mr Aguzin presided over some of the firm’s major expansion efforts during the period, including establishing itself in China as one of the few international financial institutions with a full range of services and capabilities; including a fully-owned locally incorporated commercial bank, a majority-owned securities company, an asset management company and a futures and options company. Concurrent with his Asia CEO role, Mr Aguzin also ran J.P. Morgan’s Investment Banking division in Asia. During his tenure the bank rose to become one of the leading investment banks in the Asia Pacific region.

Mr Aguzin joined J.P. Morgan in 1990 in Buenos Aires as a financial analyst. Between 1990 and 2005, he held a variety of roles in New York and Buenos Aires, and in 2005 he was appointed as CEO, Latin America. In 2008 and 2009, in addition to his responsibilities as CEO, Latin America and Head of Latin America Investment Banking, he served as Senior Country Officer for Brazil.

Mr Aguzin holds a bachelor degree in Economics from the Wharton School of the University of Pennsylvania in the US and is fluent in Spanish, Portuguese and English. 

Nicolas Aguzin joined HKEX as Chief Executive Officer on 24 May 2021 from J.P. Morgan, where he was most recently Chief Executive Officer of J.P. Morgan’s International Private Bank. Mr Aguzin has been based in Hong Kong since 2012.

From 2013 to 2020, Mr Aguzin was CEO, J.P. Morgan, Asia Pacific where he was responsible for all the firm’s business across 17 markets. Mr Aguzin presided over some of the firm’s major expansion efforts during the period, including establishing itself in China as one of the few international financial institutions with a full range of services and capabilities; including a fully-owned locally incorporated commercial bank, a majority-owned securities company, an asset management company and a futures and options company. Concurrent with his Asia CEO role, Mr Aguzin also ran J.P. Morgan’s Investment Banking division in Asia. During his tenure the bank rose to become one of the leading investment banks in the Asia Pacific region.

Mr Aguzin joined J.P. Morgan in 1990 in Buenos Aires as a financial analyst. Between 1990 and 2005, he held a variety of roles in New York and Buenos Aires, and in 2005 he was appointed as CEO, Latin America. In 2008 and 2009, in addition to his responsibilities as CEO, Latin America and Head of Latin America Investment Banking, he served as Senior Country Officer for Brazil.

Mr Aguzin holds a bachelor degree in Economics from the Wharton School of the University of Pennsylvania in the US and is fluent in Spanish, Portuguese and English. 

Managing Partner , Qiming Venture Partners

Nisa Leung is Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China with over 480 portfolio companies.

She currently sits on the board of Zai Lab (NASDAQ:ZLAB; HKSE:9688), CanSino Biologics (SSE:688185; HKSE:6185), Venus MedTech (HKSE:2500), dMed, Chain Medical Labs, Berry Oncology, Belief BioMed, ZhenGe, Valgen among others.  Her other investments include Gan & Lee (SSE:603087), New Horizon Health (HKSE:6606), Aeonmed Medical, Berry Genomics (SZSE:000710), Broncus (HKSE:2216), CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Kira Pharmaceutical, LIH, Novast Pharmaceuticals, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), Richen, Wuxi Leiming, MedX, Cure Genetics, Goodwill (SSE:688246), SinoCell Tech (SSE:688520), Sino Biological (SZSE:301047), Apollomics, Sino United, Schrödinger (NASDAQ:SDGR) , Shouti, Jacobio (HKSE:1167), Hope Medicine, Insilico Medicine, Alamar among others.

Ms Leung has been recognized by the Forbes Global 100 VC Midas List in 2019, 2020, 2021 and 2022 and named Best Women VCs List by Forbes China #1 in 2022.

Ms Leung earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council and serves as an independent non-executive director of the Hong Kong Exchanges and Clearing Limited (“HKEX”) and Hong Kong Palace Museum.

Nisa Leung is Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China with over 480 portfolio companies.

She currently sits on the board of Zai Lab (NASDAQ:ZLAB; HKSE:9688), CanSino Biologics (SSE:688185; HKSE:6185), Venus MedTech (HKSE:2500), dMed, Chain Medical Labs, Berry Oncology, Belief BioMed, ZhenGe, Valgen among others.  Her other investments include Gan & Lee (SSE:603087), New Horizon Health (HKSE:6606), Aeonmed Medical, Berry Genomics (SZSE:000710), Broncus (HKSE:2216), CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Kira Pharmaceutical, LIH, Novast Pharmaceuticals, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), Richen, Wuxi Leiming, MedX, Cure Genetics, Goodwill (SSE:688246), SinoCell Tech (SSE:688520), Sino Biological (SZSE:301047), Apollomics, Sino United, Schrödinger (NASDAQ:SDGR) , Shouti, Jacobio (HKSE:1167), Hope Medicine, Insilico Medicine, Alamar among others.

Ms Leung has been recognized by the Forbes Global 100 VC Midas List in 2019, 2020, 2021 and 2022 and named Best Women VCs List by Forbes China #1 in 2022.

Ms Leung earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council and serves as an independent non-executive director of the Hong Kong Exchanges and Clearing Limited (“HKEX”) and Hong Kong Palace Museum.

Co-Founder and CEO , BioNTech

Prof. Ugur Sahin, M.D., Co-Founder and CEO of BioNTech, is a physician, immunologist and leader in the development of novel approaches to fight cancer and infectious diseases. Prof. Sahin is one of the world’s foremost experts on messenger ribonucleic acid (mRNA) medicines. He has pioneered several breakthroughs enabling the development of mRNA vaccines and other types of immunotherapies in clinical development. Prof. Sahin initiated and oversees “Project Lightspeed,” the historic development of the first mRNA vaccine for COVID-19, moving from lab and clinical testing to conditional approval within an unprecedented 11-month period. He also leads BioNTech’s research and development of neoantigen specific mRNA cancer vaccines which are individually tailored and produced on demand according to the profile of non-synonymous mutations identified by next-generation sequencing in patients’ tumors. Since 2019, Prof. Sahin and his teams have been working on a tuberculosis vaccine program which is expected to enter clinical testing by end of 2022. If successfully developed, the company pledged to provide affordable access to the vaccine in low income countries. Prof. Sahin is co-inventor of more than 500 filed patents applications and patents. Prof. Sahin’s academic credentials include serving as a Full Professor (W3) in Translational Oncology & Immunology at Johannes Gutenberg University in Mainz, Germany, where he was the supervisor for more than 50 PhD students. He also holds the role of Chairman of the Scientific Management Board of the Helmholtz Institute for Translational Oncology (HI-TRON), also in Mainz.

Prof. Ugur Sahin, M.D., Co-Founder and CEO of BioNTech, is a physician, immunologist and leader in the development of novel approaches to fight cancer and infectious diseases. Prof. Sahin is one of the world’s foremost experts on messenger ribonucleic acid (mRNA) medicines. He has pioneered several breakthroughs enabling the development of mRNA vaccines and other types of immunotherapies in clinical development. Prof. Sahin initiated and oversees “Project Lightspeed,” the historic development of the first mRNA vaccine for COVID-19, moving from lab and clinical testing to conditional approval within an unprecedented 11-month period. He also leads BioNTech’s research and development of neoantigen specific mRNA cancer vaccines which are individually tailored and produced on demand according to the profile of non-synonymous mutations identified by next-generation sequencing in patients’ tumors. Since 2019, Prof. Sahin and his teams have been working on a tuberculosis vaccine program which is expected to enter clinical testing by end of 2022. If successfully developed, the company pledged to provide affordable access to the vaccine in low income countries. Prof. Sahin is co-inventor of more than 500 filed patents applications and patents. Prof. Sahin’s academic credentials include serving as a Full Professor (W3) in Translational Oncology & Immunology at Johannes Gutenberg University in Mainz, Germany, where he was the supervisor for more than 50 PhD students. He also holds the role of Chairman of the Scientific Management Board of the Helmholtz Institute for Translational Oncology (HI-TRON), also in Mainz.

Co-Chief Operating Officer & Co-Head of Markets , HKEX

Wilfred Yiu is Co-Chief Operating Officer and Co-Head of Markets for Hong Kong Exchanges and Clearing Limited.  Also, he is Chief Executive for Stock Exchange of Hong Kong Limited and Hong Kong Futures Exchange Limited. Previously, he was Deputy Chief Executive Officer and Chief Operating Officer for Beijing Gao Hua Securities Company Limited, and Chairman of its wholly-owned subsidiary, Qian Kun Futures Co., Ltd.  Prior to that, he was Head of Credit Structured Products for Asia at Goldman Sachs (Asia) L.L.C.

Mr Yiu served as a governor for the Board of Dalian Commodity Exchange in China from 2015 to 2017, and is currently an advisor for the Strategic Advisory Committee of Dalian Commodity Exchange.  He is an adjunct professor at the Hong Kong Polytechnic University.

Mr Yiu earned a Master’s degree in Computer Science from Stanford University and an MBA in Finance from the Stern School of Business at New York University.

Wilfred Yiu is Co-Chief Operating Officer and Co-Head of Markets for Hong Kong Exchanges and Clearing Limited.  Also, he is Chief Executive for Stock Exchange of Hong Kong Limited and Hong Kong Futures Exchange Limited. Previously, he was Deputy Chief Executive Officer and Chief Operating Officer for Beijing Gao Hua Securities Company Limited, and Chairman of its wholly-owned subsidiary, Qian Kun Futures Co., Ltd.  Prior to that, he was Head of Credit Structured Products for Asia at Goldman Sachs (Asia) L.L.C.

Mr Yiu served as a governor for the Board of Dalian Commodity Exchange in China from 2015 to 2017, and is currently an advisor for the Strategic Advisory Committee of Dalian Commodity Exchange.  He is an adjunct professor at the Hong Kong Polytechnic University.

Mr Yiu earned a Master’s degree in Computer Science from Stanford University and an MBA in Finance from the Stern School of Business at New York University.

Executive Vice President & International and China President , AstraZeneca

Leon Wang is Executive Vice President, International and China President at AstraZeneca. He is responsible for the overall strategy for the region and for driving sustainable growth across our activities in China, Asia Area, Australia, New Zealand, as well as Latin America, Brazil, Russia, Eurasia, the Middle East and Africa. As a member of AstraZeneca’s Senior Executive Team, Mr Wang reports to the CEO, Pascal Soriot.

Mr Wang joined AstraZeneca China in March 2013 as Vice President for GI, Respiratory, Anaesthesia and Antiinfection (GRA), and was promoted to President of AstraZeneca China in 2014. Under Mr Wang’s leadership, China has become AstraZeneca’s second-largest market worldwide, and AstraZeneca has become one of the fastest-growing multinational pharmaceutical companies in China. In January 2017, Mr Wang was promoted to Executive Vice President, Asia Pacific Region at AstraZeneca, with responsibility for the strategy and sustainable growth of businesses in China, Asia Area, Australia and New Zealand. In May 2017, Mr Wang further expanded his role to cover the whole international region as Executive Vice President.

As a local leader, Mr Wang grew up, studied, and developed his career in Shanghai, and he is devoted to the long-term development of AstraZeneca’s business in China as well as the nation’s pharmaceutical industry.

During his tenure, Mr Wang has advocated and driven the commercial innovation strategy in China. Focusing on the core company value of ‘Putting Patients First’, he has led the company’s efforts to establish strategic collaboration with cross-border partners, to provide innovative integrated diagnosis-and-treatment solution covering the entire patient journey and help for establishing an innovative healthcare ecosystem in the industry.

With twenty years of extensive management experience in the pharmaceutical industry, including a series of positions of increasing responsibility in marketing and business leadership at Roche, where he was a Business Unit Vice President before joining AstraZeneca, Mr Wang has developed deep and unique insights into China’s healthcare and pharmaceutical industries. 

In addition, Mr Wang holds several positions in local trade associations and other prominent organizations. These include Member of the 12th Jiangsu Provincial Committee of the Chinese People’s Political Consultative Conference, Deputy to the 16th Wuxi Municipal People’s Congress, the 8th Rotating President of China Pharmaceutical Enterprise Association, Vice Chairman of the 8 th Council of the Shanghai Association of Enterprises with Foreign Investment. 

Mr Wang holds an EMBA from China Europe International Business School, and a Bachelor of Arts from Shanghai International Studies University.

Leon Wang is Executive Vice President, International and China President at AstraZeneca. He is responsible for the overall strategy for the region and for driving sustainable growth across our activities in China, Asia Area, Australia, New Zealand, as well as Latin America, Brazil, Russia, Eurasia, the Middle East and Africa. As a member of AstraZeneca’s Senior Executive Team, Mr Wang reports to the CEO, Pascal Soriot.

Mr Wang joined AstraZeneca China in March 2013 as Vice President for GI, Respiratory, Anaesthesia and Antiinfection (GRA), and was promoted to President of AstraZeneca China in 2014. Under Mr Wang’s leadership, China has become AstraZeneca’s second-largest market worldwide, and AstraZeneca has become one of the fastest-growing multinational pharmaceutical companies in China. In January 2017, Mr Wang was promoted to Executive Vice President, Asia Pacific Region at AstraZeneca, with responsibility for the strategy and sustainable growth of businesses in China, Asia Area, Australia and New Zealand. In May 2017, Mr Wang further expanded his role to cover the whole international region as Executive Vice President.

As a local leader, Mr Wang grew up, studied, and developed his career in Shanghai, and he is devoted to the long-term development of AstraZeneca’s business in China as well as the nation’s pharmaceutical industry.

During his tenure, Mr Wang has advocated and driven the commercial innovation strategy in China. Focusing on the core company value of ‘Putting Patients First’, he has led the company’s efforts to establish strategic collaboration with cross-border partners, to provide innovative integrated diagnosis-and-treatment solution covering the entire patient journey and help for establishing an innovative healthcare ecosystem in the industry.

With twenty years of extensive management experience in the pharmaceutical industry, including a series of positions of increasing responsibility in marketing and business leadership at Roche, where he was a Business Unit Vice President before joining AstraZeneca, Mr Wang has developed deep and unique insights into China’s healthcare and pharmaceutical industries. 

In addition, Mr Wang holds several positions in local trade associations and other prominent organizations. These include Member of the 12th Jiangsu Provincial Committee of the Chinese People’s Political Consultative Conference, Deputy to the 16th Wuxi Municipal People’s Congress, the 8th Rotating President of China Pharmaceutical Enterprise Association, Vice Chairman of the 8 th Council of the Shanghai Association of Enterprises with Foreign Investment. 

Mr Wang holds an EMBA from China Europe International Business School, and a Bachelor of Arts from Shanghai International Studies University.

Founder and CIO , Lake Bleu Capital

Dr. Bin Li is the founder and CIO of Lake Bleu Capital and a former partner of Ally Bridge Group. Previously, he was a Managing Director and the Head of Greater China Healthcare Research at Morgan Stanley and led the coverage of the Greater China healthcare industry. Since he moved to Morgan Stanley and established the healthcare research practice in Hong Kong in 2008, he was recognized as the best Asia/China healthcare analyst for many years consecutively from the two well-known Wall Street investor polls - "Institutional Investor" (II) and "Greenwich", including No. 1 Asia Healthcare Analyst by II for seven consecutive years (2008-2014), No.1 China Healthcare Analyst by II for five consecutive years (2010-2014), No. 1 in Wall Street Journal's Best Asia Healthcare Analysts poll for his stock picks in 2010, and No. 1 Asia Healthcare Analyst by other investor surveys such as Greenwich and Asiamoney.

Prior to that, he was the head of Merrill Lynch Greater China Healthcare Research Team.  He also was a key member of the top-rank US pharmaceutical research team at Merrill Lynch based in New York. Before that, he worked at Merck Research Laboratory as a scientist. Dr. Li holds a Ph.D. in biochemistry and MBA from New York University, and a BA in chemistry from Fudan University.

Lake Bleu Capital is a Hong Kong-based investment platform that specializes in healthcare in Asia/Greater China. With a long-term investment horizon, it manages strategies through both public and private equity investments. Its healthcare hedge fund won multiple industry-leading performance awards, including the Winner of HFM AsiaHedge’s 5-Year Awards (over US$500mn) and the Asian Hedge Fund Awards by Eurekahedge.

Dr. Bin Li is the founder and CIO of Lake Bleu Capital and a former partner of Ally Bridge Group. Previously, he was a Managing Director and the Head of Greater China Healthcare Research at Morgan Stanley and led the coverage of the Greater China healthcare industry. Since he moved to Morgan Stanley and established the healthcare research practice in Hong Kong in 2008, he was recognized as the best Asia/China healthcare analyst for many years consecutively from the two well-known Wall Street investor polls - "Institutional Investor" (II) and "Greenwich", including No. 1 Asia Healthcare Analyst by II for seven consecutive years (2008-2014), No.1 China Healthcare Analyst by II for five consecutive years (2010-2014), No. 1 in Wall Street Journal's Best Asia Healthcare Analysts poll for his stock picks in 2010, and No. 1 Asia Healthcare Analyst by other investor surveys such as Greenwich and Asiamoney.

Prior to that, he was the head of Merrill Lynch Greater China Healthcare Research Team.  He also was a key member of the top-rank US pharmaceutical research team at Merrill Lynch based in New York. Before that, he worked at Merck Research Laboratory as a scientist. Dr. Li holds a Ph.D. in biochemistry and MBA from New York University, and a BA in chemistry from Fudan University.

Lake Bleu Capital is a Hong Kong-based investment platform that specializes in healthcare in Asia/Greater China. With a long-term investment horizon, it manages strategies through both public and private equity investments. Its healthcare hedge fund won multiple industry-leading performance awards, including the Winner of HFM AsiaHedge’s 5-Year Awards (over US$500mn) and the Asian Hedge Fund Awards by Eurekahedge.

Co-Founder, CEO and CSO , RemeGen

Dr. Jianmin Fang is the co-founder, CEO and CSO of RemeGen（09995 KH); the founder and Chairman of the Board of Directors of MabPlex International, and a Professor at the School of Life Science and Technology, Tongji University, Shanghai.  Dr. Fang has over 25 years of experience in biologics R&D and has successfully led multiple innovative drug programs from discovery through commercialization. He has over 50 drug-related invention patents and is the inventor of the marketed drugs telitacicept, disitamab vedotin, and conbercept.  Dr. Fang obtained a Ph.D. in biology from Dalhousie University, Canada, and received post-doctoral training in Harvard Medical School.

 

Dr. Jianmin Fang is the co-founder, CEO and CSO of RemeGen（09995 KH); the founder and Chairman of the Board of Directors of MabPlex International, and a Professor at the School of Life Science and Technology, Tongji University, Shanghai.  Dr. Fang has over 25 years of experience in biologics R&D and has successfully led multiple innovative drug programs from discovery through commercialization. He has over 50 drug-related invention patents and is the inventor of the marketed drugs telitacicept, disitamab vedotin, and conbercept.  Dr. Fang obtained a Ph.D. in biology from Dalhousie University, Canada, and received post-doctoral training in Harvard Medical School.

 

Managing Partner , Vivo Capital

Hongbo Lu is a Managing Partner at Vivo Capital, leading the firm’s global public market and innovation private investment strategies, and serving as the CIO for Vivo’s investments in China. Previously she was a Managing Partner at Lilly Asia Ventures (LAV) and contributed meaningfully to the growth and expansion of the platform during 2017-2020. Prior to LAV, DrLu was a Managing Director at OrbiMed and led the firm’s entry in public investments in Asia. She was one of the first few biotech specialists investing in Asia healthcare public equities since 2011. Among private investments, Dr Lu served on the boards of Turning Point Therapeutics (TPTX, acquired by BMS), CrownBio (6554.TT, acquired by JSR), Avedro (AVDR, acquired by Glaukos), Avistone, Rgenta, as well as served as a founding board member of ADARx, Elpiscience, Geneception, MedtecX, Terns, Ronovo, Ribox, and Visirna since inception. Dr Lu started her career as a bench scientist, before transitioning into biotech equity research at Piper Jaffray in early 2000. Dr Lu holds a PhD in Bioengineering from University of Washington, MBA from Haas School of Business, UC Berkeley, and is a distinguished graduate of Tsinghua University.

Hongbo Lu is a Managing Partner at Vivo Capital, leading the firm’s global public market and innovation private investment strategies, and serving as the CIO for Vivo’s investments in China. Previously she was a Managing Partner at Lilly Asia Ventures (LAV) and contributed meaningfully to the growth and expansion of the platform during 2017-2020. Prior to LAV, DrLu was a Managing Director at OrbiMed and led the firm’s entry in public investments in Asia. She was one of the first few biotech specialists investing in Asia healthcare public equities since 2011. Among private investments, Dr Lu served on the boards of Turning Point Therapeutics (TPTX, acquired by BMS), CrownBio (6554.TT, acquired by JSR), Avedro (AVDR, acquired by Glaukos), Avistone, Rgenta, as well as served as a founding board member of ADARx, Elpiscience, Geneception, MedtecX, Terns, Ronovo, Ribox, and Visirna since inception. Dr Lu started her career as a bench scientist, before transitioning into biotech equity research at Piper Jaffray in early 2000. Dr Lu holds a PhD in Bioengineering from University of Washington, MBA from Haas School of Business, UC Berkeley, and is a distinguished graduate of Tsinghua University.

Head of Listing , HKEX

Co-Head of IPO Vetting, Listing Division , HKEX

Stephanie Lau, is the Co-Head of IPO Vetting, Listing Division at the HKEX. Working in partnership with Ms. Li-Chien Wong, Ms. Lau will oversee all HKEX issuer listing applications and will lead a highly experienced team of professionals that support the continued development of Hong Kong as a global listing venue of choice. 

Ms. Lau qualified as a lawyer in Hong Kong, as well as in England and Wales, and has over 20 years of experience in corporate finance and listing related matters.  Ms. Lau also served as a Senior Vice President of Listed Issuer Regulation, Listing Division at the HKEX, prior to heading the IPO Vetting Department.

Stephanie Lau, is the Co-Head of IPO Vetting, Listing Division at the HKEX. Working in partnership with Ms. Li-Chien Wong, Ms. Lau will oversee all HKEX issuer listing applications and will lead a highly experienced team of professionals that support the continued development of Hong Kong as a global listing venue of choice. 

Ms. Lau qualified as a lawyer in Hong Kong, as well as in England and Wales, and has over 20 years of experience in corporate finance and listing related matters.  Ms. Lau also served as a Senior Vice President of Listed Issuer Regulation, Listing Division at the HKEX, prior to heading the IPO Vetting Department.

Co-Head of IPO Vetting, Listing Division , HKEX

Li-Chien Wong, is the Co-Head of IPO Vetting, Listing Division at the HKEX. Together with Stephanie Lau, Ms. Wong will have oversight of all HKEX issuer listing applications. 

Ms. Wong has 25 years of experience in private practice as a corporate and capital markets lawyer, 20 of those in Hong Kong, having advised leading investment banks and a wide range of corporates on capital market matters.

Li-Chien Wong, is the Co-Head of IPO Vetting, Listing Division at the HKEX. Together with Stephanie Lau, Ms. Wong will have oversight of all HKEX issuer listing applications. 

Ms. Wong has 25 years of experience in private practice as a corporate and capital markets lawyer, 20 of those in Hong Kong, having advised leading investment banks and a wide range of corporates on capital market matters.

Vice President of IPO Vetting, Listing Division , HKEX

Dr. Patrick Lam is the Vice President of IPO Vetting, Listing Division at the HKEX, and has supported the Division with his corporate, academia, and entrepreneurial experiences with pharmaceuticals, biologics, medical devices and service providers of the health industries since the launch of the Biotech Chapter.

Prior to the HKEX and for more than a decade, Patrick was a senior management consultant in advisory practice most recently in Monitor Deloitte, and before that PwC Hong Kong and Greater China specializing in strategy & operations for private and public sector clients in Pharmaceuticals, Life Sciences and Healthcare areas. Patrick obtained his PhD (Physiology) and completed his Postgraduate Fellowship (Medicine) at the University of Toronto.  

Dr. Patrick Lam is the Vice President of IPO Vetting, Listing Division at the HKEX, and has supported the Division with his corporate, academia, and entrepreneurial experiences with pharmaceuticals, biologics, medical devices and service providers of the health industries since the launch of the Biotech Chapter.

Prior to the HKEX and for more than a decade, Patrick was a senior management consultant in advisory practice most recently in Monitor Deloitte, and before that PwC Hong Kong and Greater China specializing in strategy & operations for private and public sector clients in Pharmaceuticals, Life Sciences and Healthcare areas. Patrick obtained his PhD (Physiology) and completed his Postgraduate Fellowship (Medicine) at the University of Toronto.  

Vice President of IPO Vetting, Listing Division , HKEX

Vernon Tam is the Vice President of IPO Vetting, Listing Division at the HKEX. He has over 15 years of healthcare and corporate finance experience. He started his career in the pharmaceutical industry in MSD and Eli Lilly, and then worked in investment banks including Deutsche Bank and Bank of China International focusing on biotechnology and healthcare sector for more than 10 years. 

Mr. Tam graduated from the University of Hong Kong with a Bachelor of Science in molecular biology and Master of Philosophy in reproductive endocrinology. He also holds an MBA degree from the Chinese University of Hong Kong and completed the international MBA program with a major in healthcare finance in Duke University. 

Vernon Tam is the Vice President of IPO Vetting, Listing Division at the HKEX. He has over 15 years of healthcare and corporate finance experience. He started his career in the pharmaceutical industry in MSD and Eli Lilly, and then worked in investment banks including Deutsche Bank and Bank of China International focusing on biotechnology and healthcare sector for more than 10 years. 

Mr. Tam graduated from the University of Hong Kong with a Bachelor of Science in molecular biology and Master of Philosophy in reproductive endocrinology. He also holds an MBA degree from the Chinese University of Hong Kong and completed the international MBA program with a major in healthcare finance in Duke University. 

Assistant Vice President of IPO Vetting, Listing Division , HKEX

Dr. Carol Chan is an Assistant Vice President of IPO Vetting, Listing Division at the HKEX, with a main focus on vetting applications and pre-IPO enquiry under Chapter 18A. She has over 13 years of pharmaceutical and biomedical research experiences. She was responsible for the medical affairs in various drugs across different therapeutic areas in Gilead Sciences and GSK. She was a postdoctoral research follow in the York University and the University of British Columbia in Canada prior to joining the pharmaceutical industry in 2015. She has a PhD in microbiology and nutrition from the University of Hong Kong.

Dr. Carol Chan is an Assistant Vice President of IPO Vetting, Listing Division at the HKEX, with a main focus on vetting applications and pre-IPO enquiry under Chapter 18A. She has over 13 years of pharmaceutical and biomedical research experiences. She was responsible for the medical affairs in various drugs across different therapeutic areas in Gilead Sciences and GSK. She was a postdoctoral research follow in the York University and the University of British Columbia in Canada prior to joining the pharmaceutical industry in 2015. She has a PhD in microbiology and nutrition from the University of Hong Kong.

Executive President , China Pharmaceutical Innovation and Research Development Association (PhIRDA)

Mr Song Ruilin, Executive President of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Advisor on Participation in and Deliberation of State Affairs for the Chinese People's Political Consultative Conference (CPPCC), Advisor on Participation in and Deliberation of State Affairs for the Central Committee of Chinese Peasants and Workers Democratic Party. He is also L.L.B. of China University of Political Science and Law, EMBA of China Europe International Business School, Doctor of Social and Administrative Pharmacy of China Pharmaceutical University and Visiting Scholar of the University of Sydney. Mr Song had served in the Legislative Affairs Office at State Council of China for a long time, engaging in health and drug policy, legal studies and in charge of law making and reviewing in the areas of pharmaceutical and healthcare industry. In recent years, he mainly engages in the research on China's pharmaceutical innovation policy.

Currently, Mr Song also undertakes several social positions, such as Executive Deputy Director of the Research Center of National Drug Policy & Ecosystem of China Pharmaceutical University, Visiting Research Fellow of Shanghai Jiao Tong University, Member of TCM Strategic Expert Consultation Committee of NMPA, Biotech Advisory Panel Member of the SEHK, Vice President of China Alliance for Rare Disease (CARD), Honorary Director of Chinese Pharmaceutical Association (CPA), Director of Chinese Pharmacists Association and Director of Bethune Charitable Foundation.

Mr Song Ruilin, Executive President of China Pharmaceutical Innovation and Research Development Association (PhIRDA), Advisor on Participation in and Deliberation of State Affairs for the Chinese People's Political Consultative Conference (CPPCC), Advisor on Participation in and Deliberation of State Affairs for the Central Committee of Chinese Peasants and Workers Democratic Party. He is also L.L.B. of China University of Political Science and Law, EMBA of China Europe International Business School, Doctor of Social and Administrative Pharmacy of China Pharmaceutical University and Visiting Scholar of the University of Sydney. Mr Song had served in the Legislative Affairs Office at State Council of China for a long time, engaging in health and drug policy, legal studies and in charge of law making and reviewing in the areas of pharmaceutical and healthcare industry. In recent years, he mainly engages in the research on China's pharmaceutical innovation policy.

Currently, Mr Song also undertakes several social positions, such as Executive Deputy Director of the Research Center of National Drug Policy & Ecosystem of China Pharmaceutical University, Visiting Research Fellow of Shanghai Jiao Tong University, Member of TCM Strategic Expert Consultation Committee of NMPA, Biotech Advisory Panel Member of the SEHK, Vice President of China Alliance for Rare Disease (CARD), Honorary Director of Chinese Pharmaceutical Association (CPA), Director of Chinese Pharmacists Association and Director of Bethune Charitable Foundation.

Executive Director and Co-CEO of Fosun International , Rotating Chairman of China Healthcare Investment 50 Forum

Chen Qiyu, Executive Director and Co-CEO of Fosun International, he has also been a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE, 600196.SH；02196.HK), a non-executive director and chairman of Shanghai Henlius (listed on the Hong Kong Stock Exchange, 02696.HK), a non-executive director and vice chairman of Sinopharm (listed on the Hong Kong Stock Exchange, 01099.HK), a director of Gland Pharma Limited (listed on the BSE Limited and National Stock Exchange of India Limited with stock code GLAND), Sanyuan Foods (listed on the SSE, 600429.SH) and various companies within the Group. 

Mr. Chen has been the chairman of China Medical Pharmaceutical Material Association, a vice chairman of China Pharmaceutical Innovation and Research Development Association, the honorary chairman and chief supervisor of Shanghai Biopharmaceutics Industry Association, the vice council chairman of Shanghai Society of Genetics, a member of the 13th Shanghai Standing Committee of the Chinese People’s Political Consultative Conference, and vice president of Shanghai Federation of Industry and Commerce (part-time).

Mr. Chen received a bachelor’s degree in genetics from Fudan University in 1993 and an EMBA degree from China Europe International Business School in 2005. 

Chen Qiyu, Executive Director and Co-CEO of Fosun International, he has also been a non-executive director of Fosun Pharma (listed on the Hong Kong Stock Exchange and the SSE, 600196.SH；02196.HK), a non-executive director and chairman of Shanghai Henlius (listed on the Hong Kong Stock Exchange, 02696.HK), a non-executive director and vice chairman of Sinopharm (listed on the Hong Kong Stock Exchange, 01099.HK), a director of Gland Pharma Limited (listed on the BSE Limited and National Stock Exchange of India Limited with stock code GLAND), Sanyuan Foods (listed on the SSE, 600429.SH) and various companies within the Group. 

Mr. Chen has been the chairman of China Medical Pharmaceutical Material Association, a vice chairman of China Pharmaceutical Innovation and Research Development Association, the honorary chairman and chief supervisor of Shanghai Biopharmaceutics Industry Association, the vice council chairman of Shanghai Society of Genetics, a member of the 13th Shanghai Standing Committee of the Chinese People’s Political Consultative Conference, and vice president of Shanghai Federation of Industry and Commerce (part-time).

Mr. Chen received a bachelor’s degree in genetics from Fudan University in 1993 and an EMBA degree from China Europe International Business School in 2005. 

Co-Head of Sales & Marketing , HKEX

Christina Bao, Managing Director, is currently the Co-Head of Sales & Marketing at HKEX. 

Ms Bao joined HKEX in 2016 as the Chief of Staff, reporting to the CE of HKEX. She was responsible for the planning and oversight of the Group’s strategic projects.

Prior to joining HKEX, Ms Bao held a number of senior positions at Ping An Bank (previously at Shenzhen Development Bank, which merged with Ping An Bank in 2010) since 2001. At Shenzhen Development Bank, she served as the Chief of Staff to the Chairman and CEO from 2005 until 2010, and was responsible for the bank’s strategic projects, Investor Relations and Public Relations. After the merger and integration of the two banks, she headed Retail e-Banking, Service & Marketing, and the Retail e-Finance Strategic Business Unit for Ping An Bank.

Ms Bao received her Master of Business Administration (Finance, General) from the Peking University of Mainland China.

 

Christina Bao, Managing Director, is currently the Co-Head of Sales & Marketing at HKEX. 

Ms Bao joined HKEX in 2016 as the Chief of Staff, reporting to the CE of HKEX. She was responsible for the planning and oversight of the Group’s strategic projects.

Prior to joining HKEX, Ms Bao held a number of senior positions at Ping An Bank (previously at Shenzhen Development Bank, which merged with Ping An Bank in 2010) since 2001. At Shenzhen Development Bank, she served as the Chief of Staff to the Chairman and CEO from 2005 until 2010, and was responsible for the bank’s strategic projects, Investor Relations and Public Relations. After the merger and integration of the two banks, she headed Retail e-Banking, Service & Marketing, and the Retail e-Finance Strategic Business Unit for Ping An Bank.

Ms Bao received her Master of Business Administration (Finance, General) from the Peking University of Mainland China.

 

Chief Financial Officer , AffaMed Therapeutics

Vijay Karwal is the Chief Financial Officer of AffaMed Therapeutics, based in Hong Kong. He brings over 25 years of global financial management and advisory experience in the healthcare industry with extensive background in business development, M&A and capital raising gained in roles in industry and as a senior investment banker. He is also an Operating Partner of leading Asian healthcare investor CBC Group and serves as an Independent Director of Mega Lifesciences PCL, headquartered in Bangkok, Thailand.

Mr Karwal joined AffaMed from Nomura International in Hong Kong, where he served as Managing Director and Head of Healthcare Investment Banking for the Asia (ex-Japan) region. Prior to Nomura, he was Chief Development Officer, Asia Pacific, as well as General Manager of China operations for DaVita Inc., the international provider of kidney care services. Mr Karwal previously held several senior investment banking roles globally, including as Co-Head of M&A at CIMB Investment Bank, Asia Pacific Head of Consumer, Retail & Healthcare coverage at RBS, as Head of Healthcare Banking in North America at ABN AMRO, and as a senior member of ABN AMRO Rothschild - the global equity capital markets joint venture between the Rothschild and ABN AMRO groups. Throughout his career he has been involved in a wide variety of advisory and financing transactions in the healthcare sector, gaining extensive global experience across postings in London, Chicago, New York, Singapore and Hong Kong.

A native of the Netherlands, Mr Karwal was educated at the University of Southampton, UK, and the University of Groningen, the Netherlands, holds a M.Sc. in Economics, and is also a CFA charterholder.

Vijay Karwal is the Chief Financial Officer of AffaMed Therapeutics, based in Hong Kong. He brings over 25 years of global financial management and advisory experience in the healthcare industry with extensive background in business development, M&A and capital raising gained in roles in industry and as a senior investment banker. He is also an Operating Partner of leading Asian healthcare investor CBC Group and serves as an Independent Director of Mega Lifesciences PCL, headquartered in Bangkok, Thailand.

Mr Karwal joined AffaMed from Nomura International in Hong Kong, where he served as Managing Director and Head of Healthcare Investment Banking for the Asia (ex-Japan) region. Prior to Nomura, he was Chief Development Officer, Asia Pacific, as well as General Manager of China operations for DaVita Inc., the international provider of kidney care services. Mr Karwal previously held several senior investment banking roles globally, including as Co-Head of M&A at CIMB Investment Bank, Asia Pacific Head of Consumer, Retail & Healthcare coverage at RBS, as Head of Healthcare Banking in North America at ABN AMRO, and as a senior member of ABN AMRO Rothschild - the global equity capital markets joint venture between the Rothschild and ABN AMRO groups. Throughout his career he has been involved in a wide variety of advisory and financing transactions in the healthcare sector, gaining extensive global experience across postings in London, Chicago, New York, Singapore and Hong Kong.

A native of the Netherlands, Mr Karwal was educated at the University of Southampton, UK, and the University of Groningen, the Netherlands, holds a M.Sc. in Economics, and is also a CFA charterholder.

Portfolio Manager, Index Strategies , E Fund Management

Zhang Zhan is a Portfolio Manager at Index Strategies team at E Fund Management. He is responsible for managing E Fund CSI Biotech Thematic ETF which is among the first batch of ETFs included in the expansion of Stock Connect scheme. Prior to the current role, Mr Zhang was a portfolio manager at Quantitative Strategies team. He has over 12 years of industry experience and holds a master’s degree in Financial Mathematics from Stanford University.

Zhang Zhan is a Portfolio Manager at Index Strategies team at E Fund Management. He is responsible for managing E Fund CSI Biotech Thematic ETF which is among the first batch of ETFs included in the expansion of Stock Connect scheme. Prior to the current role, Mr Zhang was a portfolio manager at Quantitative Strategies team. He has over 12 years of industry experience and holds a master’s degree in Financial Mathematics from Stanford University.

Co-Head of Healthcare Group, Asia Ex-Japan , Goldman Sachs

Michael Chiu is Managing Director and Co-Head of the Healthcare Investment Banking Group in Asia Ex-Japan at Goldman Sachs. 

Prior to joining GS, Michael was Managing Director and Head of Asia Healthcare Investment Banking at Bank of America Merrill Lynch. Earlier in his career, he focused on the healthcare sector in Asia across investment banking and private equity investment. Michael held positions at OrbiMed, UBS and Credit Suisse.

Michael earned a BS in Actuarial Science from the University of Michigan.

Michael Chiu is Managing Director and Co-Head of the Healthcare Investment Banking Group in Asia Ex-Japan at Goldman Sachs. 

Prior to joining GS, Michael was Managing Director and Head of Asia Healthcare Investment Banking at Bank of America Merrill Lynch. Earlier in his career, he focused on the healthcare sector in Asia across investment banking and private equity investment. Michael held positions at OrbiMed, UBS and Credit Suisse.

Michael earned a BS in Actuarial Science from the University of Michigan.

Executive Director, New Product Research , MSCI

Kumar Neeraj is an Executive Director in the new product research team at MSCI and is responsible for producing research that focusses new MSCI Index products. He has worked extensively on the development of MSCI thematic indexes and ESG indexes. More recently he has been focussing on developing MSCI thematic index framework and suite of MSCI thematic index methodologies. The New Product Development team is primarily responsible for development of new index products e.g., factor and economic exposure indexes, thematic indexes as well as the full range of capitalisation-weighted indexes. 

Prior to MSCI, Mr Neeraj was working with Credit Suisse as Assistant Vice President in Prime Services. In his role he was responsible for analysing hedge fund portfolios on a diverse set of risk issues, funding and liquidity risk and portfolio construction. At Credit Suisse he was also involved in publishing Credit Suisse “First Look”, a weekly publication that views Risk, Exposure, Returns and Capital.

Mr Neeraj holds an MBA degree in Finance from Indian School of Business and a bachelor’s degree in marine engineering.

Kumar Neeraj is an Executive Director in the new product research team at MSCI and is responsible for producing research that focusses new MSCI Index products. He has worked extensively on the development of MSCI thematic indexes and ESG indexes. More recently he has been focussing on developing MSCI thematic index framework and suite of MSCI thematic index methodologies. The New Product Development team is primarily responsible for development of new index products e.g., factor and economic exposure indexes, thematic indexes as well as the full range of capitalisation-weighted indexes. 

Prior to MSCI, Mr Neeraj was working with Credit Suisse as Assistant Vice President in Prime Services. In his role he was responsible for analysing hedge fund portfolios on a diverse set of risk issues, funding and liquidity risk and portfolio construction. At Credit Suisse he was also involved in publishing Credit Suisse “First Look”, a weekly publication that views Risk, Exposure, Returns and Capital.

Mr Neeraj holds an MBA degree in Finance from Indian School of Business and a bachelor’s degree in marine engineering.

Founding Partner and Chief Investment Officer , TruMed Investment

Iris (Ting) Wang, CFA, is the Founding Partner and Chief Investment Officer of TruMed Investment. Prior to founding TruMed, Ms. Wang was a Partner of OrbiMed and a portfolio manager of the OrbiMed New Horizons Fund. Previously, Ms. Wang was a Director at Credit Suisse and head of the Asia and China healthcare research team. She started her professional career as a management consultant at McKinsey and A.T. Kearney, focusing on healthcare and supply chain management. Ms. Wang is an M.B.A. degree holder from Columbia Business School and graduated from the Value Investing Program with Dean’s Honor in 2011. She also holds two B.S. degrees in biological science and economics from Peking University and completed major specialties in psychology.

 

Iris (Ting) Wang, CFA, is the Founding Partner and Chief Investment Officer of TruMed Investment. Prior to founding TruMed, Ms. Wang was a Partner of OrbiMed and a portfolio manager of the OrbiMed New Horizons Fund. Previously, Ms. Wang was a Director at Credit Suisse and head of the Asia and China healthcare research team. She started her professional career as a management consultant at McKinsey and A.T. Kearney, focusing on healthcare and supply chain management. Ms. Wang is an M.B.A. degree holder from Columbia Business School and graduated from the Value Investing Program with Dean’s Honor in 2011. She also holds two B.S. degrees in biological science and economics from Peking University and completed major specialties in psychology.

 

Head of China Issuer Services, Senior Vice President, Global Issuer Services , HKEX

Winnie Han is the Head of China Issuer Services and Senior Vice President of Global Issuer Services in HKEX. Her key focus is to lead the China team to promote HKEX as the top listing venue for Greater China companies. She has extensive coverage and works closely with Chinese/Southeast Asian potential issuers, investors, governments, associations and intermediaries. She is a familiar face on many New Economy, Advanced Technology or Healthcare Forums/Summits/Conferences promoting Hong Kong as the Go-To IPO destination.

Prior to her current role, Ms Han had over 15 years of experiences in China A-share investment banking at UBS and Credit Suisse. Before joining HKEX, she was the Co-Head of ECM at Credit Suisse Founder Securities. She holds China A-share Sponsor Representatives Qualification and Certified Public Accountant Qualification of China (non-practicing).

Ms Han received her Master’s degree from Peking University and Bachelor’s degree from Xiamen University.

Winnie Han is the Head of China Issuer Services and Senior Vice President of Global Issuer Services in HKEX. Her key focus is to lead the China team to promote HKEX as the top listing venue for Greater China companies. She has extensive coverage and works closely with Chinese/Southeast Asian potential issuers, investors, governments, associations and intermediaries. She is a familiar face on many New Economy, Advanced Technology or Healthcare Forums/Summits/Conferences promoting Hong Kong as the Go-To IPO destination.

Prior to her current role, Ms Han had over 15 years of experiences in China A-share investment banking at UBS and Credit Suisse. Before joining HKEX, she was the Co-Head of ECM at Credit Suisse Founder Securities. She holds China A-share Sponsor Representatives Qualification and Certified Public Accountant Qualification of China (non-practicing).

Ms Han received her Master’s degree from Peking University and Bachelor’s degree from Xiamen University.

Founder and Chief Executive Officer , BrainCo

Bicheng Han is the founder and CEO of BrainCo. BrainCo is a world-leading brain-computer interface (BCI) company and the first unicorn among all BCI companies in the world. Mr Han started BrainCo while completing his work as a PhD candidate at Harvard Center for Brain Science and has grown it into a multi-national organization with over 250 team members with offices in the USA and China. Their technology has been applied in multiple fields to help people with different needs, from neurological diseases like ADHD, Alzheimers, and Autism, to prostheses that help people with disabilities regain control over their body. For his work in BMI, he was awarded Young Global Leader by the World Economic Forum, Fortune 40 under 40 and MIT Tech Review China 35 Innovators under 35.

Bicheng Han is the founder and CEO of BrainCo. BrainCo is a world-leading brain-computer interface (BCI) company and the first unicorn among all BCI companies in the world. Mr Han started BrainCo while completing his work as a PhD candidate at Harvard Center for Brain Science and has grown it into a multi-national organization with over 250 team members with offices in the USA and China. Their technology has been applied in multiple fields to help people with different needs, from neurological diseases like ADHD, Alzheimers, and Autism, to prostheses that help people with disabilities regain control over their body. For his work in BMI, he was awarded Young Global Leader by the World Economic Forum, Fortune 40 under 40 and MIT Tech Review China 35 Innovators under 35.

Managing Director , Sequoia Capital China

Prior to joining Sequoia, Cyber Cao participated most of the investment at Vivo Capital Fund VII & VIII in China. Before that, Mr Cao was the leader of Nycomed North Asia strategy and business development, and he helped Nycomed refurbish its China business and played an integral role in its acquisition of Techpool, a leading Chinese Biopharma company. In his early career, Mr Cao was at McKinsey & Company where he worked with both multi-national and local healthcare companies on corporate strategy. Mr Cao received his M.S. in Pharmacy Administration and a B.S. in Pharmaceutics from Peking University. 

Prior to joining Sequoia, Cyber Cao participated most of the investment at Vivo Capital Fund VII & VIII in China. Before that, Mr Cao was the leader of Nycomed North Asia strategy and business development, and he helped Nycomed refurbish its China business and played an integral role in its acquisition of Techpool, a leading Chinese Biopharma company. In his early career, Mr Cao was at McKinsey & Company where he worked with both multi-national and local healthcare companies on corporate strategy. Mr Cao received his M.S. in Pharmacy Administration and a B.S. in Pharmaceutics from Peking University. 

Partner , SIG

Ryushi Shinagawa has over 10 years of investment experience in healthcare sector, leading/participating in the investment and post-investment management of Finch Therapeutics (FNCH), XtalPi, Synaptic Medical, Leader Medical, Cloud of Wisdom, and Stonewise etc. Before joining SIG, he worked in Fosun Group and HNA Group, participated in their respective healthcare investments. Mr Shinagawa received MBA from Guanghua School of Management Peking University. He also holds Bachelor of Philosophy and Bachelor of Economics from Brandeis University.

Ryushi Shinagawa has over 10 years of investment experience in healthcare sector, leading/participating in the investment and post-investment management of Finch Therapeutics (FNCH), XtalPi, Synaptic Medical, Leader Medical, Cloud of Wisdom, and Stonewise etc. Before joining SIG, he worked in Fosun Group and HNA Group, participated in their respective healthcare investments. Mr Shinagawa received MBA from Guanghua School of Management Peking University. He also holds Bachelor of Philosophy and Bachelor of Economics from Brandeis University.

Co-Founder and Chairman , XtalPi

Dr. Shuhao Wen is the co-founder and chairman of the board at XtalPi, and an adjunct professor at Zhejiang University. Prior to founding XtalPi, Dr. Wen completed his postdoctoral research at the Massachusetts Institute of Technology (MIT) and worked as a postdoctoral research scholar at the University of California at Riverside. He has published 36 papers and has 48 core patent applications, 42 PCT patents and 11 US patent application. Dr. Wen is a published quantum physicist with over 14 years of research experiences on multi-scale simulation technology, quantum-classical hybrid theory, and molecular crystal polymorphism ranking theory.

Dr. Wen co-founded XtalPi with partners at MIT in 2014 and has led several rounds of financing with an amount of nearly US$800 million. He has also contributed to the cooperation with world-leading research institutes and pharmaceutical companies including Pfizer and SSCI.

In 2019, Dr. Wen was awarded as a science and technology innovation and entrepreneurship talent in the Innovative Talent Promotion Plan of the Ministry of Science and Technology, and a science and technology entrepreneur in the National Ten Thousand Talents Program. In 2020, he was awarded as one of “Fortune’s 40 Business Elites Under 40 in China”.

Dr. Shuhao Wen is the co-founder and chairman of the board at XtalPi, and an adjunct professor at Zhejiang University. Prior to founding XtalPi, Dr. Wen completed his postdoctoral research at the Massachusetts Institute of Technology (MIT) and worked as a postdoctoral research scholar at the University of California at Riverside. He has published 36 papers and has 48 core patent applications, 42 PCT patents and 11 US patent application. Dr. Wen is a published quantum physicist with over 14 years of research experiences on multi-scale simulation technology, quantum-classical hybrid theory, and molecular crystal polymorphism ranking theory.

Dr. Wen co-founded XtalPi with partners at MIT in 2014 and has led several rounds of financing with an amount of nearly US$800 million. He has also contributed to the cooperation with world-leading research institutes and pharmaceutical companies including Pfizer and SSCI.

In 2019, Dr. Wen was awarded as a science and technology innovation and entrepreneurship talent in the Innovative Talent Promotion Plan of the Ministry of Science and Technology, and a science and technology entrepreneur in the National Ten Thousand Talents Program. In 2020, he was awarded as one of “Fortune’s 40 Business Elites Under 40 in China”.

Executive Director of Investment Banking Department , CICC

Lisa Gong is the Executive Director of Investment Banking, leading the team in completing domestic capital market financing of more than RMB 30 billion, and overseas capital market financing of more than HKD 42 billion. She has more than 10 years of experience in domestic and overseas IPOs and capital market transactions.

Lisa Gong is the Executive Director of Investment Banking, leading the team in completing domestic capital market financing of more than RMB 30 billion, and overseas capital market financing of more than HKD 42 billion. She has more than 10 years of experience in domestic and overseas IPOs and capital market transactions.

CFO , Akeso

Mr. Michael XI joined Akeso (the “Company”, 9926.HK) in November 2018 as the chief financial officer (the “CFO”) of the Company. Mr. XI is primarily responsible for overseeing the overall financial management, financial matters, investor relations, public relations and strategic development of the Company. Mr. XI has over 16 years of financial industry experience in the U.S. and China, including investment banking and private equity investment with many public and private companies. Prior to joining the Company, Mr. XI was a director at SIN Capital (HK) Limited, focusing on investments in healthcare industry in China, and was an investment banker at Credit Suisse, Morgan Stanley and CLSA securities executing high profile transactions, including IPOs, debt and equity financings and M&As for leading companies in China. Mr. Xi obtained his bachelor’s degree in biochemistry from Wuhan University, his Master of Science degree in biochemistry and computer science from Rutgers University in the US and MBA degree with distinction from Stern School of Business at New York University in the U.S.

Mr. Michael XI joined Akeso (the “Company”, 9926.HK) in November 2018 as the chief financial officer (the “CFO”) of the Company. Mr. XI is primarily responsible for overseeing the overall financial management, financial matters, investor relations, public relations and strategic development of the Company. Mr. XI has over 16 years of financial industry experience in the U.S. and China, including investment banking and private equity investment with many public and private companies. Prior to joining the Company, Mr. XI was a director at SIN Capital (HK) Limited, focusing on investments in healthcare industry in China, and was an investment banker at Credit Suisse, Morgan Stanley and CLSA securities executing high profile transactions, including IPOs, debt and equity financings and M&As for leading companies in China. Mr. Xi obtained his bachelor’s degree in biochemistry from Wuhan University, his Master of Science degree in biochemistry and computer science from Rutgers University in the US and MBA degree with distinction from Stern School of Business at New York University in the U.S.

Chairman & CEO , CBMG

Mr. Liu is the founder, Chairman, and CEO of CBMG. For the past seven years, he has been deeply involved in biomedicine and leading CBMG become a key player in the research and development of stem cell and immune cells therapy. Currently, of the six immune cell pipelines owned by CBMG, two have become best in class. In addition, there are three Stem cell pipelines owned by CBMG, including the earliest Phase II trial for AlloJoin®, its "Off-the-Shelf" allogenic haMPC therapy for the treatment of Knee Osteoarthritis (KOA). His unique strategic vision contributed to the strategic cooperation of international giants like Novartis Group.

Mr. Liu Bizuo was the Vice President of Alibaba Group, responsible for the overseas strategic investment of Alibaba Group. Before joining Alibaba Group, Mr. Liu served as the General Manager of Corporate Strategy looking after Microsoft’s China investment strategy and corporate strategic planning process.

Mr. Liu is the founder, Chairman, and CEO of CBMG. For the past seven years, he has been deeply involved in biomedicine and leading CBMG become a key player in the research and development of stem cell and immune cells therapy. Currently, of the six immune cell pipelines owned by CBMG, two have become best in class. In addition, there are three Stem cell pipelines owned by CBMG, including the earliest Phase II trial for AlloJoin®, its "Off-the-Shelf" allogenic haMPC therapy for the treatment of Knee Osteoarthritis (KOA). His unique strategic vision contributed to the strategic cooperation of international giants like Novartis Group.

Mr. Liu Bizuo was the Vice President of Alibaba Group, responsible for the overseas strategic investment of Alibaba Group. Before joining Alibaba Group, Mr. Liu served as the General Manager of Corporate Strategy looking after Microsoft’s China investment strategy and corporate strategic planning process.

Chairman and CEO , Esco Lifesciences Group

Xiangqian Lin is the Chairman and CEO of Esco Lifesciences Group. Since joining Esco, he transformed the company into a global life sciences group, growing the enterprise value by more than 300X. Now, the company has business network in more than 130 countries and around 1,700 employee. In 2021, Esco closed a record-setting USD200 million series A round led by renowned global investors Vivo Capital and Novo Holdings, with participation from China Investment Corporation EDBI and other sophisticated investors. Mr Lin has over 20 years of life science operating and investment experience. In 2018, he founded EVX Ventures, focusing on building and investing in biotech companies.

Mr Lin graduated with a BSc in Economics from The Wharton School, University of Pennsylvania.

Xiangqian Lin is the Chairman and CEO of Esco Lifesciences Group. Since joining Esco, he transformed the company into a global life sciences group, growing the enterprise value by more than 300X. Now, the company has business network in more than 130 countries and around 1,700 employee. In 2021, Esco closed a record-setting USD200 million series A round led by renowned global investors Vivo Capital and Novo Holdings, with participation from China Investment Corporation EDBI and other sophisticated investors. Mr Lin has over 20 years of life science operating and investment experience. In 2018, he founded EVX Ventures, focusing on building and investing in biotech companies.

Mr Lin graduated with a BSc in Economics from The Wharton School, University of Pennsylvania.

CFO , Innovent Biologic

Mr. Ronald Ede is the Executive Directors & Chief Financial Officer for Innovent Biologic Inc. Joined since 2017, Mr. Ede is responsible for finance, investor relations, fund, channel management and information technology of the Group.

Prior to joining the Group, from 2011 to 2016, Mr. Ede was the chief financial officer of Biosensors International Ltd. and from 2009 to 2011, he was the executive director and chief financial officer of Mindray Medical International Limited.

Mr. Ede is also an independent non-executive director for Mindray Medical International Limited (a listed company on the Shenzhen Stock Exchange with stock code: 300760) since 2006, and Dawnrays Pharmaceutical (Holding) Ltd. (a company listed on the Hong Kong Stock Exchange with stock code: 2348) since 2015, respectively.

Mr. Ede received his bachelor of business administration degree from University of Hawaii in December 1984 and master of business administration degree from University of Washington in December 1988. Mr. Ede is a fellow member of the Institute of Singapore Chartered Accountants and an A-Share independent director certified by the Shenzhen Stock Exchange.

 

Mr. Ronald Ede is the Executive Directors & Chief Financial Officer for Innovent Biologic Inc. Joined since 2017, Mr. Ede is responsible for finance, investor relations, fund, channel management and information technology of the Group.

Prior to joining the Group, from 2011 to 2016, Mr. Ede was the chief financial officer of Biosensors International Ltd. and from 2009 to 2011, he was the executive director and chief financial officer of Mindray Medical International Limited.

Mr. Ede is also an independent non-executive director for Mindray Medical International Limited (a listed company on the Shenzhen Stock Exchange with stock code: 300760) since 2006, and Dawnrays Pharmaceutical (Holding) Ltd. (a company listed on the Hong Kong Stock Exchange with stock code: 2348) since 2015, respectively.

Mr. Ede received his bachelor of business administration degree from University of Hawaii in December 1984 and master of business administration degree from University of Washington in December 1988. Mr. Ede is a fellow member of the Institute of Singapore Chartered Accountants and an A-Share independent director certified by the Shenzhen Stock Exchange.

 

CFO , Zai Lab

Billy Cho is our chief financial officer since March 2018. Prior to joining Zai Lab, Mr. Cho was the Managing Director and Head of Asia Healthcare Investment Banking at Citigroup. Based in Hong Kong since 2011, Mr. Cho was responsible for healthcare client coverage at Citigroup across the Asia Pacific region and led many important biopharma transactions in China including Zai Lab’s US IPO. Prior to this, he was based in New York in healthcare M&A investment banking and also spent time in corporate development for a pharmaceutical services company. Mr. Cho started his career at Ernst & Young performing financial audits of US-based healthcare companies. Mr. Cho earned his M.B.A. from the Wharton School of the University of Pennsylvania and M.A. in Accounting from University of Virginia.

Billy Cho is our chief financial officer since March 2018. Prior to joining Zai Lab, Mr. Cho was the Managing Director and Head of Asia Healthcare Investment Banking at Citigroup. Based in Hong Kong since 2011, Mr. Cho was responsible for healthcare client coverage at Citigroup across the Asia Pacific region and led many important biopharma transactions in China including Zai Lab’s US IPO. Prior to this, he was based in New York in healthcare M&A investment banking and also spent time in corporate development for a pharmaceutical services company. Mr. Cho started his career at Ernst & Young performing financial audits of US-based healthcare companies. Mr. Cho earned his M.B.A. from the Wharton School of the University of Pennsylvania and M.A. in Accounting from University of Virginia.

Head of Healthcare Research Team , CICC

Mr. Peng Zou is CICC healthcare research team head. He joined CICC in August 2013. He has over 12 years research experience in healthcare sector. Before CICC, he worked in Chang Jiang Security Company for 3 years as healthcare analyst. Mr Zou graduated from Wu Han University with master degree in biology. His honors and awards include:  in the past four years, his team continually won the best healthcare research team in Great China in the rank of Asiamoney and II.

Mr. Peng Zou is CICC healthcare research team head. He joined CICC in August 2013. He has over 12 years research experience in healthcare sector. Before CICC, he worked in Chang Jiang Security Company for 3 years as healthcare analyst. Mr Zou graduated from Wu Han University with master degree in biology. His honors and awards include:  in the past four years, his team continually won the best healthcare research team in Great China in the rank of Asiamoney and II.

Managing Director and Head of Asia Healthcare Research , Citi

John Yung is a Managing Director and Head of Asia Healthcare Research, based in the Citi Hong Kong office. He joined Citi Research in 2015. He has been covering China healthcare since 2009, gaining experience at multiple firms, including CICC, CLSA, and Macquarie. Before 2009, John was employed in the biotech/pharma industry, where he worked at Amgen at the Thousand Oaks headquarters and at Pfizer in Hong Kong and La Jolla. John and his team were ranked No. 1 in healthcare research in the Institutional Investor All-Asia Research Poll from 2017 to 2019 and 2022. John holds a B.S. degree in Bioengineering (Biotech) from the University of California San Diego and an MBA degree from The Hong Kong University of Science and Technology. He is a CFA Charterholder.

John Yung is a Managing Director and Head of Asia Healthcare Research, based in the Citi Hong Kong office. He joined Citi Research in 2015. He has been covering China healthcare since 2009, gaining experience at multiple firms, including CICC, CLSA, and Macquarie. Before 2009, John was employed in the biotech/pharma industry, where he worked at Amgen at the Thousand Oaks headquarters and at Pfizer in Hong Kong and La Jolla. John and his team were ranked No. 1 in healthcare research in the Institutional Investor All-Asia Research Poll from 2017 to 2019 and 2022. John holds a B.S. degree in Bioengineering (Biotech) from the University of California San Diego and an MBA degree from The Hong Kong University of Science and Technology. He is a CFA Charterholder.

Director and Head of China Healthcare Research team , Credit Suisse

Yang Huang is a Director and Head of Credit Suisse’s China Healthcare Research team. Prior to Credit Suisse, Dr Huang was the Senior Analyst covering China healthcare at BofA in Hong Kong. Before moving to Hong Kong, he worked in Citi biotech research team in New York. Dr Huang's equity research work was supported by his experience in healthcare consulting and his academic research at the National Institutes of Health in the US. Dr Huang obtained his bachelor's degree from Nanjing University and got his PhD degree from Rutgers University. His PhD work focuses on computational biology, combining algorithm, AI and large-scale biological/medical data analysis. Dr Huang also is a CFA charter holder.

Yang Huang is a Director and Head of Credit Suisse’s China Healthcare Research team. Prior to Credit Suisse, Dr Huang was the Senior Analyst covering China healthcare at BofA in Hong Kong. Before moving to Hong Kong, he worked in Citi biotech research team in New York. Dr Huang's equity research work was supported by his experience in healthcare consulting and his academic research at the National Institutes of Health in the US. Dr Huang obtained his bachelor's degree from Nanjing University and got his PhD degree from Rutgers University. His PhD work focuses on computational biology, combining algorithm, AI and large-scale biological/medical data analysis. Dr Huang also is a CFA charter holder.

Head of Index Strategic Research , Hang Seng Indexes Company

Gary Chiu works as the Head of Index Strategic Research at Hang Seng Indexes Company. His role is to build Hang Seng Indexes Company’s leading position among professional investors through insightful sharing. He has 20 years’ experience as Research Analyst covering power utilities, renewables and infrastructure sectors in Asia-Pacific during 1996-2016, and 4 years’ experience as an Investor Relations Director in a listed company in 2016-2020 before joining Hang Seng Indexes Company.

Gary Chiu works as the Head of Index Strategic Research at Hang Seng Indexes Company. His role is to build Hang Seng Indexes Company’s leading position among professional investors through insightful sharing. He has 20 years’ experience as Research Analyst covering power utilities, renewables and infrastructure sectors in Asia-Pacific during 1996-2016, and 4 years’ experience as an Investor Relations Director in a listed company in 2016-2020 before joining Hang Seng Indexes Company.

Managing Director, Head of Asia (ex. Japan ex. Australia) Healthcare Equity Research , Jefferies

Christopher Lui is a Managing Director at Jefferies leading the firm’s Asia (ex. Japan ex. Australia) healthcare equity research efforts. He has 15+ years of experience covering Greater China and ASEAN healthcare in bulge bracket and regional investment banks. He has participated in and led 30+ healthcare IPOs in HK and US. He also worked in a global healthcare specialist fund prior to joining Jefferies. Christopher has a BSc in Biochemistry and BSc in Mathematical Economics from the University of Wisconsin - Madison.

Christopher Lui is a Managing Director at Jefferies leading the firm’s Asia (ex. Japan ex. Australia) healthcare equity research efforts. He has 15+ years of experience covering Greater China and ASEAN healthcare in bulge bracket and regional investment banks. He has participated in and led 30+ healthcare IPOs in HK and US. He also worked in a global healthcare specialist fund prior to joining Jefferies. Christopher has a BSc in Biochemistry and BSc in Mathematical Economics from the University of Wisconsin - Madison.